Close

C85H168O4

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

A synthetic chiral mycolic acid analogue comprising 3-hydroxypropanoic acid having a tetracosanyl group at position 2 and a further long-chain alkyl group containing cyclopropyl, methoxy and methyl functions attached at position 3.
  • TCR Vector Products

  • TCR Cell Products

  • TCR Viral Particles

Loading...
  • Target Species:
  • TCR Clone:
  • Host Species:
  • Epitope:
  • Allele:
  • Vector Type:
CAT Product Name Target Species TCR Clone Host Species Epitope Allele Vector Type Inquiry & Datasheet
TCR-YC0290 Human anti-C85H168O4 T cell receptor (Clone 20), pCDTCR1 Mycobacterium tuberculosis clone 20 Human (2R)-2-[(1R)-1-hydroxy-16-{(1R,2S)-2-[(17R,18R)-17-methoxy-18-methylhexatriacontyl]cyclopropyl}hexadecyl]hexacosanoic acid human CD1b Lentiviral vector   Add to Cart   Datasheet
TCR-YC0291 Human anti-C85H168O4 T cell receptor (Clone 28 C58L), pCDTCR1 Mycobacterium tuberculosis clone 28 C58L Human (2R)-2-[(1R)-1-hydroxy-16-{(1R,2S)-2-[(17R,18R)-17-methoxy-18-methylhexatriacontyl]cyclopropyl}hexadecyl]hexacosanoic acid human CD1b Lentiviral vector   Add to Cart   Datasheet
TCR-YC0292 Human anti-C85H168O4 T cell receptor (DN1), pCDTCR1 Mycobacterium tuberculosis DN1 Human (2R)-2-[(1R)-1-hydroxy-16-{(1R,2S)-2-[(17R,18R)-17-methoxy-18-methylhexatriacontyl]cyclopropyl}hexadecyl]hexacosanoic acid human CD1b Lentiviral vector   Add to Cart   Datasheet
TCR-YC0293 Human anti-C85H168O4 T cell receptor (GEM18), pCDTCR1 Mycobacterium tuberculosis GEM18 Human (2R)-2-[(1R)-1-hydroxy-16-{(1R,2S)-2-[(17R,18R)-17-methoxy-18-methylhexatriacontyl]cyclopropyl}hexadecyl]hexacosanoic acid human CD1b Lentiviral vector   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.